Semaglutide – (910463-68-2)

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes and chronic weight management. Semaglutide mimics the GLP-1 hormone, which is released in the gut in response to eating, and helps to regulate blood sugar levels by stimulating insulin secretion and reducing glucagon production. For weight management, it works by suppressing appetite and promoting a feeling of fullness.

In clinical trials, semaglutide has demonstrated significant efficacy in reducing body weight. For instance, in a study of 2,000 obese adults, participants using semaglutide lost an average of 15% of their body weight after 68 weeks, compared to a 2.4% weight loss in those who only made lifestyle changes. However, weight loss tends to be regained once the medication is discontinued.

The most common side effects of semaglutide include gastrointestinal issues such as nausea, vomiting, diarrhea, constipation, and abdominal pain. These side effects are usually mild and tend to diminish over time. More serious side effects, though rare, include pancreatitis, gallbladder problems, and thyroid tumors. Semaglutide is contraindicated in patients with a history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes and chronic weight management. Semaglutide mimics the GLP-1 hormone, which is released in the gut in response to eating, and helps to regulate blood sugar levels by stimulating insulin secretion and reducing glucagon production. For weight management, it works by suppressing appetite and promoting a feeling of fullness.

In clinical trials, semaglutide has demonstrated significant efficacy in reducing body weight. For instance, in a study of 2,000 obese adults, participants using semaglutide lost an average of 15% of their body weight after 68 weeks, compared to a 2.4% weight loss in those who only made lifestyle changes. However, weight loss tends to be regained once the medication is discontinued.

The most common side effects of semaglutide include gastrointestinal issues such as nausea, vomiting, diarrhea, constipation, and abdominal pain. These side effects are usually mild and tend to diminish over time. More serious side effects, though rare, include pancreatitis, gallbladder problems, and thyroid tumors. Semaglutide is contraindicated in patients with a history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.
Sources:
https://en.wikipedia.org/wiki/Semaglutide
https://pubchem.ncbi.nlm.nih.gov/compound/56843331
https://www.medchemexpress.com/Semaglutide.html
https://www.medkoo.com/products/17091
https://www.uclahealth.org/news/article/semaglutide-weight-loss-what-you-need-know
https://www.mayoclinic.org/drugs-supplements/semaglutide-subcutaneous-route/description/drg-20406730
IUPAC Name

18-[[(1R)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S, 3R)-2-[[(2S)-2-[[(2S, 3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-2-methylpropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S, 3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-18-oxooctadecanoic acid

CAS

910463-68-2

Molecular Weight

4114

Molecular Formula

C187H291N45O59

SMILES

CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC6=CN=CN6)N

No products in the cart.